Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia.

Expert review of hematology - 1 Oct 2024

Hatashima Alycia, Shadman Mazyar

Abstract excerpt

INTRODUCTION: Bruton's tyrosine kinaseinhibitors (BTKis) changed the trajectory of upfront and relapsed/refractory chronic lymphocytic leukemia (CLL) treatment. However, BTKis are plagued by a spectrum of toxicities. Zanubrutinib was developed to circumvent challenges with prolonged tolerability by increasing BTK selectivity and maximizing efficacy through pharmacokinetic/pharmacodynamic optimization. However,...

Topics

Join the communities discussing this publication.

Adenine
Agammaglobulinaemia Tyrosine Kinase
Benzamides
Leukemia, Lymphocytic, Chronic, B-Cell
Piperidines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39163531
DOI: 10.1080/17474086.2024.2391097

Genes

BTK
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia.PMID 39163531Read ↗

Zanubrutinib: Coming of Age for BTK Inhibitors in the Treatment of Chronic Lymphocytic Leukemia?Semantic proximity Read ↗

SOHO State of the Art Updates and Next Questions: Updates on BTK Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future DirectionsSemantic proximity Read ↗

A Review of Resistance Mechanisms to Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

BRUTON’S TYROSINE KINASE (BTK) MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A CLINICAL VIEW.Semantic proximity Read ↗

Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and ProspectsSemantic proximity Read ↗

BTK inhibitors in CLL: second-generation drugs and beyond.Semantic proximity Read ↗

Pirtobrutinib at the Crossroads: Shaping Its Future Role in Chronic Lymphocytic Leukemia (CLL) Care.Semantic proximity Read ↗

Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy.Semantic proximity Read ↗

Resisting the Resistance: Navigating BTK Mutations in Chronic Lymphocytic Leukemia (CLL).Semantic proximity Read ↗

Pirtobrutinib in Chronic Lymphocytic Leukemia: Navigating Resistance and the Personalisation of BTK-Targeted TherapySemantic proximity Read ↗

Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/TP53 Mutation: SEQUOIA Arm D Results.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.